Discovery of a Highly Subtype-Selective AURKA PROTAC Degrader (CT3) with Superior Activity to the Inhibitor for Hematological Malignancies.
Aurora kinases, especially AURKA, are critical for mitotic regulation, and their dysregulation is linked to tumorigenesis, making AURKA a promising anticancer target. Conventional ATP-competitive AURKA inhibitors suffer from low subtype selectivity and failure to disrupt noncatalytic functions, resulting in limited the...